A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Multiple Myeloma
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: N/AIntervention Model: Sequential AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The study may enroll approximately 80 subjects in total.
The study may enroll approximately 80 subjects in total.
Tracking Information
- NCT #
- NCT04244656
- Collaborators
- Not Provided
- Investigators
- Study Director: Ewelina Morawa, MD CRISPR Therapeutics
Get Well Soon